An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
IMPLANET Signs a Distribution Agreement With Sanyou Medical in China and a Technological Partnership for the Development of a New Product Range
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Very Positive)
Tags
partnership
Rhea-AI Summary
Implanet has signed a distribution agreement for its JAZZ® platform in China and established a technology partnership with Sanyou Medical. This collaboration, following a previous capital increase, positions Implanet to leverage Sanyou’s market leadership to access China’s vast spine surgery market, which performs approximately 765,000 surgeries annually. The agreement also aims to develop a new European hybrid fixation system utilizing advanced technologies like robotics and artificial intelligence.
Positive
Signed a distribution agreement for JAZZ® platform in China, accessing the world's largest spine surgery market.
Collaborating with Sanyou Medical to develop a new European hybrid fixation system, enhancing innovation.
Negative
None.
Finalization of the distribution agreement in China for Implanet's JAZZ® platform
Technological know-how synergies for the development of a brand-new European hybrid fixation system range
BORDEAUX, France & BOSTON--(BUSINESS WIRE)--
Regulatory News:
IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME equity savings plans) (Paris:ALIMP), a medical technology company specializing in vertebral implants, announces today the signing of a distribution agreement for its JAZZ® range in China and a technology partnership with Sanyou Medical.
Ludovic LASTENNET, Implanet’s Chief Executive Officer, stated: “In continuation of the capital increase we completed with the support of Sanyou Medical, we are proud to further strengthen the strategic partnership between our two groups, this time on a commercial and technological level. The distribution agreement we signed will enable us to market our entire JAZZ® range in China, the world's largest market, and for which the regulatory files are already being initiated with the Chinese health authorities. On the technological side, this agreement enables us to leverage our respective expertise by jointly developing a new and innovative range of fixation systems for the Western markets. Lastly, the reconciliation we are making today with one of the largest manufacturers of medical devices in China will give us rapid access to leading technologies and know-how in the field of spinal surgery.”
In accordance with the partnership plan communicated on June 29, 2022 and following the success of the capital increase carried out with the support of Sanyou Medical, the collaboration between the two groups is taking shape with the signature of two agreements, the first commercial and the second technological.
The commercial agreement signed covers the distribution of Implanet's JAZZ® platform by Sanyou Medical in China. China is the world's largest spine surgery market in terms of volume, with 15,000 pediatric scoliosis surgeries and 750,000 adult surgeries performed per year1. Implanet intends to take advantage of Sanyou Medical's leadership in its domestic market as the second largest Chinese manufacturer of medical devices for spine surgery to deploy its solutions on a long-term basis. The registration of Implanet's proprietary JAZZ® range with the Chinese health authorities is also underway.
The technological alliance between Implanet and Sanyou Medical will enable the synergy of the two groups' technological know-how and R&D in order to accelerate their product innovation policy. This partnership aims to jointly develop a brand-new European hybrid fixation system range, incorporating the very latest developments and innovations in the field of spine surgery (deformation treatment system, minimally invasive range, robotics, artificial intelligence, etc.).
Upcoming financial press release: 2022 annual Revenue, on January 17, 2023, after market close
About Sanyou Medical
Founded in 2005, Shanghai Sanyou Medical Co, Ltd. is a company dedicated to the R&D, manufacturing and sales of innovative and independent orthopedic products. The main products of Shanghai Sanyou are spinal and trauma implants. Shanghai Sanyou is one of the few companies with the ability to make original innovations based on clinical requirements in the field of spinal implants in China.
The Company has established a complete product development system with world-class R&D equipment and project management systems to ensure that its products are advanced, effective and reliable. By the end of 2021, the company had 27 registration certificates for Class III medical devices and 395 patents registered including 61 in inventions, 214 in utility models, 116 in designs and 4 in software copyrights.
About IMPLANET
Founded in 2007, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its activity revolves around a comprehensive innovative solution for improving the treatment of spinal pathologies (JAZZ®) complemented by the product range offered by Orthopaedic & Spine Development (OSD), acquired in May 2021 (thoraco-lumbar screws, cages and cervical plates). Implanet’s tried-and-tested orthopedic platform is based on the traceability of its products. Protected by four families of international patents, JAZZ® has obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States, the CE mark in Europe and ANVISA approval in Brazil. IMPLANET employs 39 staff and recorded a consolidated revenue of €6.1 million in 2021. Based near Bordeaux in France, IMPLANET opened a US subsidiary in Boston in 2013. IMPLANET is listed on the Euronext Growth market in Paris. For further information, please visit www.Implanet.com.
NewCap
Media Relations
Arthur Rouillé
Tél.: +33 (0)1 44 71 94 94
Implanet@newcap.eu
Source: IMPLANET
FAQ
What is the significance of Implanet's distribution agreement in China for stock symbol IMPZY?
Implanet's distribution agreement allows it to market their JAZZ® platform in China, tapping into a lucrative market with 765,000 annual surgeries, which could potentially boost revenue for stock symbol IMPZY.
How will the technology partnership with Sanyou Medical affect Implanet's future?
The partnership with Sanyou Medical is expected to accelerate product innovation and allow the development of advanced spinal systems that could enhance Implanet's product offerings and market competitiveness.
What is the expected impact of the JAZZ® platform in China's market on IMPZY stock?
With the JAZZ® platform's entry into China, analysts speculate a positive impact on IMPZY stock due to potential increased sales in a large market.
When will Implanet announce its annual revenue for 2022?
Implanet plans to release its 2022 annual revenue report on January 17, 2023, after market close.
What are the expected technological advancements from the partnership with Sanyou Medical?
The partnership aims to develop a new range of European hybrid fixation systems incorporating innovations such as robotics and artificial intelligence, which could enhance Implanet's product portfolio.